AMAG Pharmaceuticals, Inc. Sustainability Profile
AMAG Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies primarily focused on women's health, maternal health, and supportive care. With a strong presence in North America and expanding operations in international markets, AMAG is dedicated to addressing unmet medical needs. The company’s core products, including treatments for iron deficiency anaemia and preterm labour, are distinguished by their commitment to safety and efficacy. AMAG's notable achievements include a robust pipeline of therapies that leverage cutting-edge research and development. As a trusted name in the biopharmaceutical sector, AMAG Pharmaceuticals continues to enhance patient outcomes and solidify its market position through strategic partnerships and a focus on innovation.
DitchCarbon Score
How does AMAG Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AMAG Pharmaceuticals, Inc.'s score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
In 2024, AMAG Pharmaceuticals, Inc. reported total carbon emissions of approximately 93.2 million kg CO2e. This figure includes 92.2 million kg CO2e from Scope 1 emissions, which primarily arise from direct operations, and about 972,600 kg CO2e from Scope 3 emissions, specifically related to purchased goods and services. Notably, there were no reported Scope 2 emissions for the year. The company has not disclosed any specific reduction targets or initiatives as part of its climate commitments. Additionally, there are no significant achievements in emissions reduction reported. The emissions data for AMAG Pharmaceuticals is cascaded from its parent company, Azurity Pharmaceuticals, Inc., indicating a corporate family relationship that influences its environmental reporting. Overall, AMAG Pharmaceuticals, Inc. is positioned within an industry context that increasingly prioritises sustainability, yet it currently lacks defined climate pledges or reduction strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 104,400,000 | 000,000,000 | 000,000,000 | - | - | 00,000,000 |
| Scope 2 | - | - | - | - | - | - |
| Scope 3 | - | - | 0,000,000,000 | - | - | 000,000 |
How Carbon Intensive is AMAG Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is AMAG Pharmaceuticals, Inc.'s Location?
AMAG Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
AMAG Pharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2019, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 1% of total emissions under the GHG Protocol, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
AMAG Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AMAG Pharmaceuticals, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.